Amgen’s MariTide Shows Promising Results in Phase 2 Obesity Study, Offers Hope for Type 2 Diabetes Patients
Amgen Inc. has announced promising results from its Phase 2 obesity study of MariTide, a potential groundbreaking treatment for obesity, particularly in patients with type 2 diabetes.
2 minutes to read